NYSE:TEVA

Teva Pharmaceutical (TEVA)

34.43
+1.60 (4.87%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
69 watching
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Teva Pharmaceutical, traded under the symbol TEVA-N, has shown significant improvement, gaining 264% since the new CEO took office in January 2023, suggesting a robust turnaround for the company. After experiencing a rough period post-2002, recent positive financial results indicate that the company's performance is on the upswing. The headquarters in Israel underline its position as a large-cap player in the pharmaceutical industry. Under the current market conditions, Teva is ranked #1 in its ADR/CDR universe, benefiting from a rotation towards drug stocks. Its stock broke through the $21 barrier in September, continuing its upward trend with strong accumulation for the past six months, despite not currently offering a dividend. Analysts are optimistic about its prospects, projecting a price target of $34.50.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Pfeizer, PFE
BUY
One of the world's largest genetic drug manufactor company. The stock has dropped in the last few weeks. This is a good opportunity to buy stocks.
TOP PICK
Wonderful company. Not overvalued.
BUY ON WEAKNESS
Generic drugs is a great sector. This one is the leader. Accumulate on a gradual basis.
HOLD
Generic drug space is a good place to be. A little high now.
TOP PICK
Generic drugs have done very well. Have increased their margins regularily. Steadily moving up.
BUY
Good growth trend. Good products. May drop in the near term.
TOP PICK
Likes the generic drug sector.
PAST TOP PICK
(Was a top pick on Aug 23. Up 1%) Still likes. Likess the generic sector in drugs.
TOP PICK
Stable revenue stream and earnings record. Likes the generic drug sector.
PAST TOP PICK
(Was a top pick on Mar 15. Up 19%.) Still likes.
PAST TOP PICK
(Was a top pick on June 21. Up 7.1%) Good long term story.
TOP PICK
Over 50 new drugs waiting approval. Cheap.
TOP PICK
Global. Good acquisitions. Because it is based in Israel, price has dropped inordinately.
TOP PICK
World leader in generic drugs.
PAST TOP PICK
(Was a top pick on Jan 25/01 up 11%) Still likes, but may be fully valued now.
Showing 256 to 270 of 274 entries